Lori Wirth, MD | Authors

May 12, 2022

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

April 20, 2022

Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.

April 19, 2022

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

April 08, 2022

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

March 30, 2022

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.